NDA 220848 · Msd
Lipfendra
Enlicitide Decanoate · Oral
NovelPriority reviewCDER novel approval, Jul 15, 2026: To reduce low-density lipoprotein cholesterol
Last checked: Nov 20, 2026Latest source record: Jul 15, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2026
Jul 15, 2026
Approved uses
1
Original approval plus efficacy supplements
Registered trials
26
8 Phase 3, 3 recruiting
FAERS reports
41
6 serious, 0 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Jul 15, 2026.
LIPFENDRA ® is indicated as an adjunct to diet and exercise to reduce low-density lipoprotein cholesterol (LDL-C) in adults with hypercholesterolemia, including heterozygous familial hypercholesterolemia (HeFH). Cardiovascular outcomes trials have demonstrated that reducing LDL-C lowers the risk for major adverse cardiovascular events (MACE) in adults at increased risk when treated with statins or monoclonal antibody proprotein convertase subtilisin kexin type 9 (PCSK9) inhibitors as an add-on to statin therapy. LIPFENDRA is a proprotein convertase subtilisin kexin type 9 (PCSK9) inhibitor indicated as an adjunct to diet and exercise to reduce low-density lipoprotein cholesterol (LDL-C) in adults with hypercholesterolemia, including heterozygous familial hypercholesterolemia (HeFH). Cardiovascular outcomes trials have demonstrated that reducing LDL-C lowers the risk for major adverse cardiovascular events (MACE) in adults at increased risk when treated with statins or monoclonal antibody PCSK9 inhibitors as an add-on to statin therapy. ( 1 )
Mechanism: Enlicitide is a macrocyclic peptide that binds to PCSK9. PCSK9 binds to the low-density lipoprotein receptors (LDLR) on the surface of hepatocytes to promote LDLR degradation within the liver. By inhibiting the binding of PCSK9 to LDLR, enlicitide increases the number of LDLRs available to clear LDL-C, thereby lowering LDL-C levels.
Therapeutic areas: Cardiovascular and metabolic
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Jul 15, 2026 Original approval · Type 1 - New Molecular Entity · priority review NovelLetterReviewLabel
1 products under this application
- LIPFENDRA · ENLICITIDE DECANOATE EQ 20MG BASE · TABLET, ORAL · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Enlicitide Decanoate" as an intervention, any sponsor and status, largest first.
- Enlicitide Decanoate (MK-0616 Oral PCSK9 Inhibitor) Cardiovascular Outcomes Study (MK-0616-015) CORALreef OutcomesPivotal-lookingActive, not recruiting
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT06008756 · 14,550 participants (planned) · Start Oct 9, 2023 · Primary completion Nov 29, 2029
Drug: Enlicitide Decanoate; Placebo · For: Arteriosclerosis; Hypercholesterolaemia
Sites: Alexander City, Alabama; Birmingham, Alabama; Daphne, Alabama · 669 sites in all
- Open-label Extension Study of Enlicitide Decanoate (MK-0616/Enlicitide Oral PCSK9 Inhibitor) in Adults With Hypercholesterolemia (MK-0616-019) CORALreef ExtensionPivotal-lookingActive, not recruiting
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT06492291 · 3,000 participants (planned) · Start Aug 5, 2024 · Primary completion Oct 13, 2028
Drug: Enlicitide Decanoate · For: Hypercholesterolemia
Sites: Daphne, Alabama; Foley, Alabama; Phoenix, Arizona · 222 sites in all
- A Study of Enlicitide Decanoate (MK-0616 Oral PCSK9 Inhibitor) in Adults With Hypercholesterolemia (MK-0616-013) CORALreef LipidsPivotal-lookingCompleted
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT05952856 · 2,912 participants · Start Aug 10, 2023 · Primary completion Jul 28, 2025
Drug: Enlicitide Decanoate; Placebo · For: Hypercholesterolemia; Familial Hypercholesterolemia
Sites: Daphne, Alabama; Foley, Alabama; Phoenix, Arizona · 168 sites in all
- A Clinical Study of Enlicitide in Participants With High Cholesterol (MK-0616-037)Pivotal-lookingCompleted
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT07216482 · 996 participants · Start Nov 11, 2025 · Primary completion Aug 3, 2026
Drug: Enlicitide; Rosuvastatin and 2 more · For: Hyperlipidemia
Sites: Birmingham, Alabama; Foley, Alabama; Phoenix, Arizona · 87 sites in all
- A Clinical Trial of MK-7262 and Enlicitide in Participants With High Lipoprotein(a) (MK-7262-004)Pivotal-lookingRecruiting
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT07614984 · 750 participants (planned) · Start Jun 30, 2026 · Primary completion Oct 12, 2027
Drug: MK-7262; Enlicitide and 2 more · For: Lipoprotein(a)
Sites: Alexander City, Alabama; Mobile, Alabama; Beverly Hills, California · 77 sites in all
- A Study of Enlicitide Decanoate (MK-0616 Oral PCSK9 Inhibitor) in Adults With Heterozygous Familial Hypercholesterolemia (MK-0616-017/CORALreef HeFH)Pivotal-lookingCompleted
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT05952869 · 303 participants · Start Aug 8, 2023 · Primary completion Apr 7, 2025
Drug: Enlicitide Decanoate; Placebo · For: Hypercholesterolemia; Familial Hypercholesterolemia
Sites: Daphne, Alabama; Boca Raton, Florida; Cutler Bay, Florida · 59 sites in all
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT06450366 · 301 participants · Start Jul 8, 2024 · Primary completion Feb 14, 2025
Drug: Enlicitide; Ezetimibe and 1 more · For: Hypercholesterolemia
Sites: Lincoln, California; Flossmoor, Illinois; Louisville, Kentucky · 35 sites in all
- A Study of Enlicitide Decanoate (MK-0616, an Oral PCSK9 Inhibitor) in Children and Adolescents With Heterozygous Familial Hypercholesterolemia (MK-0616-029)Pivotal-lookingRecruiting
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT07058077 · 153 participants (planned) · Start Aug 21, 2025 · Primary completion Dec 4, 2033
Drug: Enlicitide Decanoate; Placebo · For: Heterozygous Familial Hypercholesterolemia (HeFH)
Sites: Wilmington, Delaware; Washington D.C., District of Columbia; Boca Raton, Florida · 50 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- diarrhoea7
- dizziness5
- headache5
- nausea5
- fatigue3
- feeling abnormal3
- inappropriate schedule of product administration3
- myalgia3
- no adverse event3
- pain in extremity3
- bladder pain2
- cerebrovascular accident2
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2026 | 41 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Efficacy and Safety of Oral PCSK9 Inhibitor Enlicitide in Adults With Heterozygous Familial Hypercholesterolemia: A Randomized Clinical Trial.
Ballantyne CM, Gellis L, Tardif JC, et al. · JAMA 2026 · Clinical Trial, Phase III, Multicenter Study
- A Placebo-Controlled Trial of the Oral PCSK9 Inhibitor Enlicitide.
Navar AM, Mikhailova E, Catapano AL, et al. · N Engl J Med 2026 · Clinical Trial, Phase III, Multicenter Study
- Oral PCSK9 Inhibitor Enlicitide Versus Oral Nonstatin Therapies: A Phase 3 Randomized Clinical Trial.
Catapano AL, Mikhailova E, Navar AM, et al. · J Am Coll Cardiol 2026 · Randomized Controlled Trial, Clinical Trial, Phase III
Sponsor: Merck & Co.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.